Free Trial
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Lyra Therapeutics logo
$0.26
-0.02 (-7.17%)
(As of 11/1/2024 ET)

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Key Stats

Today's Range
$0.26
$0.29
50-Day Range
$0.22
$0.34
52-Week Range
$0.21
$6.79
Volume
829,665 shs
Average Volume
1.64 million shs
Market Capitalization
$16.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Hold

Company Overview

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

LYRA MarketRank™: 

Lyra Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 423rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Lyra Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lyra Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyra Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyra Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lyra Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lyra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.27% of the outstanding shares of Lyra Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Lyra Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyra Therapeutics has recently decreased by 24.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lyra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lyra Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.27% of the outstanding shares of Lyra Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Lyra Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyra Therapeutics has recently decreased by 24.91%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    9 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.69% of the stock of Lyra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lyra Therapeutics' insider trading history.
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LYRA Stock News Headlines

Lyra Therapeutics, Inc. (LYRA)
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

LYRA Stock Analysis - Frequently Asked Questions

Lyra Therapeutics' stock was trading at $5.24 at the beginning of 2024. Since then, LYRA shares have decreased by 95.1% and is now trading at $0.2589.
View the best growth stocks for 2024 here
.

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its earnings results on Wednesday, August, 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.05. The firm earned $0.60 million during the quarter, compared to analyst estimates of $0.43 million. Lyra Therapeutics had a negative net margin of 5,570.88% and a negative trailing twelve-month return on equity of 102.22%.

Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

Last Earnings
8/14/2024
Today
11/02/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$11.00
Low Stock Price Target
$0.50
Potential Upside/Downside
+1,638.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-62,680,000.00
Net Margins
-5,570.88%
Pretax Margin
-5,567.64%

Debt

Sales & Book Value

Annual Sales
$1.56 million
Book Value
$1.56 per share

Miscellaneous

Free Float
62,387,000
Market Cap
$16.95 million
Optionable
Optionable
Beta
-0.02
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:LYRA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners